Glucagon-like peptide-1 and-2 levels in children with diabetic ketoacidosis.

Basit Öğe Kaydı
dc.authorscopusid7003868986
dc.authorscopusid35847182800
dc.authorscopusid6505704665
dc.contributor.authorAkinci A.
dc.contributor.authorAydin O.
dc.contributor.authorÖzerol H.I.
dc.date.accessioned2024-08-04T20:02:17Z
dc.date.available2024-08-04T20:02:17Z
dc.date.issued2009
dc.departmentİnönü Üniversitesien_US
dc.description.abstractThe aim of this study was to investigate whether insulin deficiency and increased catabolism may have a role in the regulation of plasma glucagon-like peptide (GLP)-1 and GLP-2 levels in children with diabetic ketoacidosis (DKA) and whether insulin treatment may affect the levels of these polypeptides. Plasma GLP-1 and -2 levels were measured in 24 patients with DKA aged 8 to 14 years before insulin infusion (time 0), when ketonemia and acidosis disappeared (time 1), and when weight gain started (time 2). Eighteen healthy children aged 8 to 14 years constituted the control group. At time 0, mean plasma GLP-1 and GLP-2 levels were significantly elevated in the patients compared with the control group (p<0.05 and p<0.01, respectively). At time 1 when ketonemia and acidosis disappeared, GLP-1 and GLP-2 levels decreased significantly from the initial levels (p<0.05 and p<0.01, respectively). At this time, while GLP-1 level was not different from that of the controls, GLP-2 level was higher than that of the controls (p<0.05). GLP-1 and-2 levels did not show any significant differences between the patients and controls when weight gain started (time 2). Our results show that DKA is associated with increased plasma GLP-1 and -2 concentrations. Effective fluid and insulin treatment resulted in a significant decrease in plasma GLP-1 and -2 levels. This may be due to the negative feedback effect of insulin on the production of these polypeptides.en_US
dc.identifier.endpage150en_US
dc.identifier.issn1308-5735
dc.identifier.issue3en_US
dc.identifier.pmid21274399en_US
dc.identifier.scopus2-s2.0-84855161271en_US
dc.identifier.scopusqualityQ2en_US
dc.identifier.startpage144en_US
dc.identifier.urihttps://hdl.handle.net/11616/91558
dc.identifier.volume1en_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.relation.ispartofJournal of clinical research in pediatric endocrinologyen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectantidiabetic agenten_US
dc.subjectglucagon like peptide 1en_US
dc.subjectglucagon like peptide 2en_US
dc.subjectinsulinen_US
dc.subjectadolescenten_US
dc.subjectarticleen_US
dc.subjectblooden_US
dc.subjectcase control studyen_US
dc.subjectchilden_US
dc.subjectdiabetic ketoacidosisen_US
dc.subjectfemaleen_US
dc.subjecthumanen_US
dc.subjectinsulin dependent diabetes mellitusen_US
dc.subjectmaleen_US
dc.subjectAdolescenten_US
dc.subjectCase-Control Studiesen_US
dc.subjectChilden_US
dc.subjectDiabetes Mellitus, Type 1en_US
dc.subjectDiabetic Ketoacidosisen_US
dc.subjectFemaleen_US
dc.subjectGlucagon-Like Peptide 1en_US
dc.subjectGlucagon-Like Peptide 2en_US
dc.subjectHumansen_US
dc.subjectHypoglycemic Agentsen_US
dc.subjectInsulinen_US
dc.subjectMaleen_US
dc.titleGlucagon-like peptide-1 and-2 levels in children with diabetic ketoacidosis.en_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

Scopus İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu